/
GEHC
$63.75-$1.30 (-2.01%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$29.9B
455M shares
52-week range
$58.75 – $89.77
16% from low
Sector
X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$3.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $16.63B | $17.16B | $17.59B | $18.34B | $19.55B | $19.67B | $20.63B |
| Cost of revenue | $10.09B | $10.40B | $10.41B | $11.16B | $11.63B | $11.47B | $12.38B |
| Gross profit | $6.55B | $6.77B | $7.17B | $7.18B | $7.92B | $8.21B | $8.25B |
| Gross margin | 39.4% | 39.4% | 40.8% | 39.1% | 40.5% | 41.7% | 40.0% |
| R&D | $833.0M | $810.0M | $816.0M | $1.03B | $1.21B | $1.31B | $1.26B |
| Operating income | $2.12B | $2.72B | $2.79B | $2.52B | $2.44B | $2.63B | $2.76B |
| EBITDA | $2.84B | $3.41B | $3.54B | $3.17B | $3.51B | $3.67B | $3.79B |
| Net income | $1.52B | $13.85B | $2.25B | $1.92B | $1.57B | $1.99B | $2.08B |
| Net margin | 9.2% | 80.7% | 12.8% | 10.4% | 8.0% | 10.1% | 10.1% |
| EPS (diluted) | 3.35 | 4.41 | 4.90 | 4.22 | 3.02 | 4.34 | 4.55 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $21.8B | $4.88 | $4.85–$4.89 | 13 |
| 2027 | $22.8B | $5.40 | $5.17–$5.52 | 13 |
| 2028 | $23.9B | $6.02 | $5.63–$6.47 | 9 |
| 2029 | $25.4B | $6.73 | $6.62–$6.81 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$165.99
Price
$63.74
Implied upside
+160%
Peer comparison
GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
www.gehealthcare.com- Employees
- 54,000
- IPO / List date
- Dec 15, 2022
- HQ
- CHICAGO, IL
Held by traders on TradeandTell
No one on the platform currently holds GEHC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 254,100 | $18.1M |
| Bridgewater Associatesas of 2026-03-31 | 71,811 | $5.1M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 0.22% ($0.14/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-02 | $0.0350 | 2026-05-15 |
| 2026-01-09 | $0.0350 | 2026-02-13 |
| 2025-10-24 | $0.0350 | 2025-11-14 |
| 2025-07-25 | $0.0350 | 2025-08-15 |
| 2025-04-25 | $0.0350 | 2025-05-15 |
| 2025-01-14 | $0.0350 | 2025-02-14 |
| 2024-10-18 | $0.0300 | 2024-11-15 |
| 2024-07-19 | $0.0300 | 2024-08-15 |
| 2024-04-18 | $0.0300 | 2024-05-15 |
| 2024-01-12 | $0.0300 | 2024-02-15 |
Recent trades on TradeandTell
No one on the platform has traded GEHC yet.
